Drugs / EXS74539
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07517198 | Apr 2026 → Mar 2029 expected | gastric cancer, head and neck squamous cell carcinoma, liver cancer, non-small cell lung carcinoma +5 | Exscientia AI Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXS74539 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07517198 ↗ |
| Route | Oral | “Oral administration” NCT07517198 ↗ |